Patryk Kubiszewski1,2,3, Lansing Sugita1,2,3, Christina Kourkoulis1,2,3,4, Zora DiPucchio1,2, Kristin Schwab1,2, Christopher D Anderson1,2,3,4, M Edip Gurol1,2, Steven M Greenberg1,2, Anand Viswanathan1,2, Jonathan Rosand1,2,3,4, Alessandro Biffi1,2,4,5. 1. Hemorrhagic Stroke Research Program, J. Philip Kistler Stroke Research Center, Boston, Massachusetts. 2. Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts. 3. Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts. 4. Henry and Allison McCance Center for Brain Health, Massachusetts General Hospital, Boston, Massachusetts. 5. Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts.
Abstract
IMPORTANCE: Selective serotonin reuptake inhibitors (SSRIs) are widely used to treat poststroke depression but are associated with increased incidence of first-ever intracerebral hemorrhage (ICH) in the general population. The decision to treat ICH survivors with SSRIs must therefore balance potential risks of ICH recurrence with presumed benefits on depressive symptoms. OBJECTIVE: To determine whether SSRI use among survivors of primary ICH was associated with ICH recurrence and decreased severity of depressive symptoms. DESIGN, SETTING, AND PARTICIPANTS: Longitudinal ICH cohort study at a tertiary care center enrolling from January 2006 to December 2017, with follow-up for a median of 53.2 months (interquartile range, 42.3-61.2 months). The study included 1279 consenting individuals (1049 White, 89 Black, 77 Hispanic, and 64 other race/ethnicity) of 1335 eligible patients presenting with primary ICH and who were discharged alive from initial hospitalization for stroke. MAIN OUTCOMES AND MEASURES: We conducted univariable and multivariable analyses for ICH recurrence risk and depression severity, including subset analyses for patients with 1 or more of the following characteristics associated with high ICH recurrence risk: (1) lobar ICH; (2) presence of the apolipoprotein ε2/ε4 gene variants; (3) prior history of ICH/TIA/ischemic stroke; and (4) Black or Hispanic race/ethnicity. RESULTS: Mean age of study participants was 71.3 years, with 602 women (47%); of the 1279 participants, 1049 were White, 89 were Black, 77 were Hispanic, and 64 were other race/ethnicity. SSRI exposure was associated with both ICH recurrence (subhazard ratio [SHR], 1.31; 95% CI, 1.08-1.59) and resolution of post-ICH depression (SHR, 1.53; 95% CI, 1.12 2.09). Among those individuals at high risk for recurrent ICH, SSRIs were associated with further elevation in risk for ICH recurrence (SHR, 1.79; 95% CI, 1.22-2.64) compared with all other survivors of ICH (SHR, 1.20; 95% CI, 1.01-1.42; P = .008 for comparison of effect sizes). The association of SSRI with reduced depressive symptoms did not differ between high those at high risk for recurrent ICH and all other ICH survivors. CONCLUSIONS AND RELEVANCE: Selective serotonin reuptake inhibitor exposure after ICH is associated with both improvement in depressive symptoms and increased risk of recurrent hemorrhagic stroke. Clinical history, neuroimaging data, and genetic biomarkers may help to identify survivors of ICH more likely to safely tolerate SSRI use.
IMPORTANCE: Selective serotonin reuptake inhibitors (SSRIs) are widely used to treat poststroke depression but are associated with increased incidence of first-ever intracerebral hemorrhage (ICH) in the general population. The decision to treat ICH survivors with SSRIs must therefore balance potential risks of ICH recurrence with presumed benefits on depressive symptoms. OBJECTIVE: To determine whether SSRI use among survivors of primary ICH was associated with ICH recurrence and decreased severity of depressive symptoms. DESIGN, SETTING, AND PARTICIPANTS: Longitudinal ICH cohort study at a tertiary care center enrolling from January 2006 to December 2017, with follow-up for a median of 53.2 months (interquartile range, 42.3-61.2 months). The study included 1279 consenting individuals (1049 White, 89 Black, 77 Hispanic, and 64 other race/ethnicity) of 1335 eligible patients presenting with primary ICH and who were discharged alive from initial hospitalization for stroke. MAIN OUTCOMES AND MEASURES: We conducted univariable and multivariable analyses for ICH recurrence risk and depression severity, including subset analyses for patients with 1 or more of the following characteristics associated with high ICH recurrence risk: (1) lobar ICH; (2) presence of the apolipoprotein ε2/ε4 gene variants; (3) prior history of ICH/TIA/ischemic stroke; and (4) Black or Hispanic race/ethnicity. RESULTS: Mean age of study participants was 71.3 years, with 602 women (47%); of the 1279 participants, 1049 were White, 89 were Black, 77 were Hispanic, and 64 were other race/ethnicity. SSRI exposure was associated with both ICH recurrence (subhazard ratio [SHR], 1.31; 95% CI, 1.08-1.59) and resolution of post-ICH depression (SHR, 1.53; 95% CI, 1.12 2.09). Among those individuals at high risk for recurrent ICH, SSRIs were associated with further elevation in risk for ICH recurrence (SHR, 1.79; 95% CI, 1.22-2.64) compared with all other survivors of ICH (SHR, 1.20; 95% CI, 1.01-1.42; P = .008 for comparison of effect sizes). The association of SSRI with reduced depressive symptoms did not differ between high those at high risk for recurrent ICH and all other ICH survivors. CONCLUSIONS AND RELEVANCE: Selective serotonin reuptake inhibitor exposure after ICH is associated with both improvement in depressive symptoms and increased risk of recurrent hemorrhagic stroke. Clinical history, neuroimaging data, and genetic biomarkers may help to identify survivors of ICH more likely to safely tolerate SSRI use.
Authors: Amanda G Thrift; Tharshanah Thayabaranathan; George Howard; Virginia J Howard; Peter M Rothwell; Valery L Feigin; Bo Norrving; Geoffrey A Donnan; Dominique A Cadilhac Journal: Int J Stroke Date: 2016-10-28 Impact factor: 5.266
Authors: Miriam R Raffeld; Alessandro Biffi; Thomas W K Battey; Alison M Ayres; Anand Viswanathan; Steven M Greenberg; Jonathan Rosand; Christopher D Anderson Journal: Neurology Date: 2015-06-26 Impact factor: 9.910
Authors: Janis Brakowski; Simona Spinelli; Nadja Dörig; Oliver Gero Bosch; Andrei Manoliu; Martin Grosse Holtforth; Erich Seifritz Journal: J Psychiatr Res Date: 2017-04-24 Impact factor: 4.791
Authors: Alessandro Biffi; Christopher D Anderson; Thomas W K Battey; Alison M Ayres; Steven M Greenberg; Anand Viswanathan; Jonathan Rosand Journal: JAMA Date: 2015-09-01 Impact factor: 56.272
Authors: Alessandro Biffi; Destiny Bailey; Christopher D Anderson; Alison M Ayres; Edip M Gurol; Steven M Greenberg; Jonathan Rosand; Anand Viswanathan Journal: JAMA Neurol Date: 2016-08-01 Impact factor: 18.302
Authors: Ellis S van Etten; M Edip Gurol; Jeroen van der Grond; Joost Haan; Anand Viswanathan; Kristin M Schwab; Alison M Ayres; Ale Algra; Jonathan Rosand; Mark A van Buchem; Gisela M Terwindt; Steven M Greenberg; Marieke J H Wermer Journal: Neurology Date: 2016-09-02 Impact factor: 9.910
Authors: Anna Palumbo; Viswanath Aluru; Jessica Battaglia; Daniel Geller; Alan Turry; Marc Ross; Adrian Cristian; Caitlin Balagula; Gbenga Ogedegbe; Latika Khatri; Moses V Chao; Robert C Froemke; Jacek K Urbanek; Preeti Raghavan Journal: Am J Phys Med Rehabil Date: 2021-12-06 Impact factor: 3.412
Authors: Juan Pablo Castello; Marco Pasi; Patryk Kubiszewski; Jessica R Abramson; Andreas Charidimou; Christina Kourkoulis; Zora DiPucchio; Kristin Schwab; Christopher D Anderson; M Edip Gurol; Steven M Greenberg; Jonathan Rosand; Anand Viswanathan; Alessandro Biffi Journal: Stroke Date: 2021-09-30 Impact factor: 7.914
Authors: Sophia Keins; Jessica R Abramson; Juan Pablo Castello; Marco Pasi; Andreas Charidimou; Christina Kourkoulis; Zora DiPucchio; Kristin Schwab; Christopher D Anderson; M Edip Gurol; Steven M Greenberg; Jonathan Rosand; Anand Viswanathan; Alessandro Biffi Journal: BMC Neurol Date: 2021-12-10 Impact factor: 2.903